In this episode of MedTech Global Insights, we explore the dynamic and challenging world of cardiovascular drug-eluting stents (DES). We uncover the technological evolution from early generation devices to today's advanced bioresorbable scaffolds and discuss the immense clinical impact they have had. While innovation is thriving, bringing a new DES to the global market is a formidable task. We delve into the complex, fragmented, and ever-changing regulatory landscapes in key regions like the European Union, Asia, and Latin America. This episode provides a strategic overview of how MedTech companies can overcome these hurdles to ensure their life-saving technology reaches patients worldwide. Consider this common scenario: A MedTech scaleup has developed a revolutionary new stent with stellar US clinical data. They are ready for global expansion but are immediately overwhelmed by the disparate regulatory demands of the EU, Japan, and Brazil. Their team is spending countless hours reformatting dossiers and searching for reliable local partners, causing launch delays that cost millions and postpone critical patient care. How can they turn this roadblock into a streamlined global launchpad? Key Takeaways: - What are the critical differences between first and second-generation drug-eluting stents? - Why does a successful FDA submission not guarantee a smooth path to CE marking in Europe? - How can you leverage a single technical dossier for submissions in over 30 different countries? - What is the role of an in-country representative, and why is it essential for market access? - How is AI transforming the process of regulatory intelligence and submission management? - What are the most common pitfalls to avoid when planning a multi-market product launch? - How do post-market surveillance requirements differ between major international markets? - What strategies can help you select the most promising new markets for your device? For more information, contact us at [email protected] or visit https://pureglobal.com/